Director George L. Sing filed a Form 4 with the SEC on November 18, 2026, disclosing the sale of 2,000 shares of Regeneron Pharmaceuticals, Inc. common stock across November 16 and November 17, 2026.
Key Highlights
- Reporting person: George L. Sing, identified as a Director of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
- November 16 sale: 1,000 shares sold at a volume-weighted average price of $960.26, with individual prices ranging from $960.00 to $960.42.
- November 17 sales: Three separate transactions totaling 1,000 shares: 176 shares at $956.96, 359 shares at a volume-weighted average of $957.49 (ranging from $957.24 to $957.76), and 465 shares at a volume-weighted average of $958.11 (ranging from $958.01 to $958.13).
- Post-transaction direct holdings: 23,147 shares of common stock held directly following all reported transactions.
- Indirect holdings: An additional 2,150 shares held indirectly: 750 shares by spouse, 400 shares by spouse/custodian for son, and 1,000 shares by a trust for son.
Sing's Four-Transaction Sale of Regeneron Common Stock
According to the filing, George L. Sing, a director of Regeneron Pharmaceuticals, Inc., sold a combined 2,000 shares of the company's common stock over two trading days. On November 16, 2026, Sing disposed of 1,000 shares at a volume-weighted average price of $960.26, with actual sale prices ranging from $960.00 to $960.42, reducing his directly held shares to 24,147. The filing notes that full details on the number of shares sold at each separate price will be provided upon request by Commission staff, the company, or a security holder.
On November 17, 2026, three additional sale transactions were reported. Sing sold 176 shares at $956.96, then 359 shares at a volume-weighted average price of $957.49 (with a price range of $957.24 to $957.76), and 465 shares at a volume-weighted average price of $958.11 (with a price range of $958.01 to $958.13). The same offer to provide granular per-price detail upon request applies to both November 17 weighted-average transactions, according to the filing. Following all four transactions, Sing's directly held position stood at 23,147 shares.
In addition to his direct holdings, the filing discloses that Sing beneficially owns 2,150 shares indirectly: 750 shares held by his spouse, 400 shares held by his spouse as custodian for his son, and 1,000 shares held in a trust for his son. No derivative securities transactions were reported. All transactions are listed under transaction code "S," indicating open-market sales. The filing does not indicate that any transaction was made pursuant to a Rule 10b5-1 plan.
What Was Disclosed
George L. Sing, a Regeneron Pharmaceuticals director, disclosed four open-market sales totaling 2,000 shares of common stock on November 16-17, 2026, leaving him with 23,147 directly held shares and 2,150 indirectly held shares following the transactions.





Please wait processing your request...